169 related articles for article (PubMed ID: 27443291)
21. Genotoxic Stress Induces Senescence-Associated ADAM10-Dependent Release of NKG2D MIC Ligands in Multiple Myeloma Cells.
Zingoni A; Cecere F; Vulpis E; Fionda C; Molfetta R; Soriani A; Petrucci MT; Ricciardi MR; Fuerst D; Amendola MG; Mytilineos J; Cerboni C; Paolini R; Cippitelli M; Santoni A
J Immunol; 2015 Jul; 195(2):736-48. PubMed ID: 26071561
[TBL] [Abstract][Full Text] [Related]
22. Autocyclized and oxidized forms of SCR7 induce cancer cell death by inhibiting nonhomologous DNA end joining in a Ligase IV dependent manner.
Vartak SV; Swarup HA; Gopalakrishnan V; Gopinatha VK; Ropars V; Nambiar M; John F; Kothanahally SKS; Kumari R; Kumari N; Ray U; Radha G; Dinesh D; Pandey M; Ananda H; Karki SS; Srivastava M; Charbonnier JB; Choudhary B; Mantelingu K; Raghavan SC
FEBS J; 2018 Nov; 285(21):3959-3976. PubMed ID: 30230716
[TBL] [Abstract][Full Text] [Related]
23. HSP70 inhibition reverses cell adhesion mediated and acquired drug resistance in multiple myeloma.
Nimmanapalli R; Gerbino E; Dalton WS; Gandhi V; Alsina M
Br J Haematol; 2008 Aug; 142(4):551-61. PubMed ID: 18503584
[TBL] [Abstract][Full Text] [Related]
24. Preferential in vivo DNA repair of melphalan-induced damage in human genes is greatly affected by the local chromatin structure.
Souliotis VL; Dimopoulos MA; Episkopou HG; Kyrtopoulos SA; Sfikakis PP
DNA Repair (Amst); 2006 Aug; 5(8):972-85. PubMed ID: 16781199
[TBL] [Abstract][Full Text] [Related]
25. SCR7 is neither a selective nor a potent inhibitor of human DNA ligase IV.
Greco GE; Matsumoto Y; Brooks RC; Lu Z; Lieber MR; Tomkinson AE
DNA Repair (Amst); 2016 Jul; 43():18-23. PubMed ID: 27235626
[TBL] [Abstract][Full Text] [Related]
26. The role of nonhomologous DNA end joining, conservative homologous recombination, and single-strand annealing in the cell cycle-dependent repair of DNA double-strand breaks induced by H(2)O(2) in mammalian cells.
Frankenberg-Schwager M; Becker M; Garg I; Pralle E; Wolf H; Frankenberg D
Radiat Res; 2008 Dec; 170(6):784-93. PubMed ID: 19138034
[TBL] [Abstract][Full Text] [Related]
27. ATR addiction in multiple myeloma: synthetic lethal approaches exploiting established therapies.
Botrugno OA; Bianchessi S; Zambroni D; Frenquelli M; Belloni D; Bongiovanni L; Girlanda S; Di Terlizzi S; Ferrarini M; Ferrero E; Ponzoni M; Marcatti M; Tonon G
Haematologica; 2020 Oct; 105(10):2440-2447. PubMed ID: 33054085
[TBL] [Abstract][Full Text] [Related]
28. RECQ1 helicase is involved in replication stress survival and drug resistance in multiple myeloma.
Viziteu E; Klein B; Basbous J; Lin YL; Hirtz C; Gourzones C; Tiers L; Bruyer A; Vincent L; Grandmougin C; Seckinger A; Goldschmidt H; Constantinou A; Pasero P; Hose D; Moreaux J
Leukemia; 2017 Oct; 31(10):2104-2113. PubMed ID: 28186131
[TBL] [Abstract][Full Text] [Related]
29. The persistence of immunophenotypically normal residual bone marrow plasma cells at diagnosis identifies a good prognostic subgroup of symptomatic multiple myeloma patients.
Paiva B; Vidriales MB; Mateo G; Pérez JJ; Montalbán MA; Sureda A; Montejano L; Gutiérrez NC; García de Coca A; de las Heras N; Mateos MV; López-Berges MC; García-Boyero R; Galende J; Hernández J; Palomera L; Carrera D; Martínez R; de la Rubia J; Martín A; González Y; Bladé J; Lahuerta JJ; Orfao A; San-Miguel JF;
Blood; 2009 Nov; 114(20):4369-72. PubMed ID: 19755674
[TBL] [Abstract][Full Text] [Related]
30. [Effect of PARP1 inhibitor PJ34 on multi-drug resistance in human multiple myeloma cell line and its relationship with FA/BRCA pathway].
Xiong T; Wei H; Chen X; Xiao H
Zhonghua Yi Xue Yi Chuan Xue Za Zhi; 2014 Jun; 31(3):312-6. PubMed ID: 24928009
[TBL] [Abstract][Full Text] [Related]
31. XRCC1-mediated DNA repair is associated with progression-free survival of multiple myeloma patients after autologous stem cell transplant.
Persaud AK; Li J; Johnson JA; Seligson N; Sborov DW; Duah E; Cho YK; Wang D; Phelps MA; Hofmeister CC; Poi MJ
Mol Carcinog; 2019 Dec; 58(12):2327-2339. PubMed ID: 31544312
[TBL] [Abstract][Full Text] [Related]
32. Extent of damage and repair in the p53 tumor-suppressor gene after treatment of myeloma patients with high-dose melphalan and autologous blood stem-cell transplantation is individualized and may predict clinical outcome.
Dimopoulos MA; Souliotis VL; Anagnostopoulos A; Papadimitriou C; Sfikakis PP
J Clin Oncol; 2005 Jul; 23(19):4381-9. PubMed ID: 15883412
[TBL] [Abstract][Full Text] [Related]
33. Induction therapy in a multiple myeloma mouse model using a combination of AS101 and melphalan, and the activity of AS101 in a tumor microenvironment model.
Hayun M; Saida H; Albeck M; Peled A; Haran-Ghera N; Sredni B
Exp Hematol; 2009 May; 37(5):593-603. PubMed ID: 19375650
[TBL] [Abstract][Full Text] [Related]
34. Single-Strand Annealing Plays a Major Role in Double-Strand DNA Break Repair following CRISPR-Cas9 Cleavage in
Zhang WW; Matlashewski G
mSphere; 2019 Aug; 4(4):. PubMed ID: 31434745
[TBL] [Abstract][Full Text] [Related]
35. Modulation of melphalan and cisplatin cytotoxicity in human ovarian cancer cells resistant to alkylating drugs.
Gornati D; Zaffaroni N; Villa R; De Marco C; Silvestrini R
Anticancer Drugs; 1997 Jun; 8(5):509-16. PubMed ID: 9215615
[TBL] [Abstract][Full Text] [Related]
36. Gene-specific formation and repair of DNA monoadducts and interstrand cross-links after therapeutic exposure to nitrogen mustards.
Souliotis VL; Dimopoulos MA; Sfikakis PP
Clin Cancer Res; 2003 Oct; 9(12):4465-74. PubMed ID: 14555520
[TBL] [Abstract][Full Text] [Related]
37. Establishment of a monoclonal antibody to human myeloma cell: relation to chemotherapy and extramedullar infiltration.
Kuribayashi N; Hata H; Matsuzaki H; Yoshida M; Sonoki T; Nagasaki A; Kimura T; Harada N; Takatsuki K
Med Oncol; 1998 Dec; 15(4):248-54. PubMed ID: 9951688
[TBL] [Abstract][Full Text] [Related]
38. Association between transcriptional activity, local chromatin structure, and the efficiencies of both subpathways of nucleotide excision repair of melphalan adducts.
Episkopou H; Kyrtopoulos SA; Sfikakis PP; Fousteri M; Dimopoulos MA; Mullenders LH; Souliotis VL
Cancer Res; 2009 May; 69(10):4424-33. PubMed ID: 19417135
[TBL] [Abstract][Full Text] [Related]
39. Halting pro-survival autophagy by TGFβ inhibition in bone marrow fibroblasts overcomes bortezomib resistance in multiple myeloma patients.
Frassanito MA; De Veirman K; Desantis V; Di Marzo L; Vergara D; Ruggieri S; Annese T; Nico B; Menu E; Catacchio I; Ria R; Racanelli V; Maffia M; Angelucci E; Derudas D; Fumarulo R; Dammacco F; Ribatti D; Vanderkerken K; Vacca A
Leukemia; 2016 Mar; 30(3):640-8. PubMed ID: 26487273
[TBL] [Abstract][Full Text] [Related]
40. Targeting DNA double-strand break repair: is it the right way for sensitizing cells to 5-fluorouracil?
El-Awady RA; Saleh EM; Dahm-Daphi J
Anticancer Drugs; 2010 Mar; 21(3):277-87. PubMed ID: 20075715
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
